| High Dose Radiotherapy for Palliation (Hi-D) (NCT07291895) | British Columbia Cancer Agency | 2027-03-01 |
| A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies (NCT07621146) | British Columbia Cancer Agency | 2026-09-15 |
| Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy (NCT06885671) | British Columbia Cancer Agency | 2026-06-08 |
| HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG (NCT07295171) | British Columbia Cancer Agency | 2026-02-18 |
| Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers (NCT06918951) | British Columbia Cancer Agency | 2025-12-04 |
| Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life (NCT07255001) | British Columbia Cancer Agency | 2025-12-01 |
| Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment (NCT06574620) | British Columbia Cancer Agency | 2025-11-28 |
| Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma (NCT07210749) | British Columbia Cancer Agency | 2025-11-01 |
| Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer (NCT06835725) | British Columbia Cancer Agency | 2025-09-04 |
| Dynamic Whole Body PET/ MRI (NCT04495959) | British Columbia Cancer Agency | 2025-08-01 |
| DOTATATE PET for Meningioma Radiation Planning (NCT06937268) | British Columbia Cancer Agency | 2025-06-01 |
| Time Restricted Eating in Haematological Malignancies (NCT06862323) | British Columbia Cancer Agency | 2025-06-01 |
| Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer (NCT06665178) | British Columbia Cancer Agency | 2025-03-31 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies (NCT06208735) | British Columbia Cancer Agency | 2025-01-02 |
| STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision (NCT05576831) | British Columbia Cancer Agency | 2024-11-25 |
| NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study (NCT06650709) | British Columbia Cancer Agency | 2024-11-01 |
| Preliminary Assessment of [18F]BL40 in PET/CT Scans (NCT06224309) | British Columbia Cancer Agency | 2024-06-10 |
| Monitoring and Managing Glucose Levels in People With Pancreatic Cancer (NCT05132244) | British Columbia Cancer Agency | 2024-04-16 |
| Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer (NCT06200974) | British Columbia Cancer Agency | 2024-02-01 |
| Evidence Development in Cancer Treatment - Real World: PREDiCTrw (NCT06242912) | British Columbia Cancer Agency | 2024-01-22 |
| Diagnostic CT Palliative Radiotherapy: Feasibility Study of Treating Bone Metastases Without a CT Simulation (NCT06235034) | British Columbia Cancer Agency | 2024-01-20 |
| 177Lu-HTK03170 in mCRPC With PSMA Positive Disease (NCT05570994) | British Columbia Cancer Agency | 2024-01-01 |
| A Case Crossover Study of Intermittent Fasting in CLL/SLL (NCT05708326) | British Columbia Cancer Agency | 2023-06-12 |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs (NCT04915144) | British Columbia Cancer Agency | 2023-01-15 |
| PATH Trial: Personalized Approaches in the Treatment of Head and Neck Cancer (NCT05373251) | British Columbia Cancer Agency | 2022-08-01 |
| CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease (NCT05257967) | British Columbia Cancer Agency | 2022-07-18 |
| RAPid SimPLE Targeted Radiation Treatment for Brain Metastases (NCT05050929) | British Columbia Cancer Agency | 2022-07-01 |
| 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients. (NCT05025878) | British Columbia Cancer Agency | 2021-10-20 |
| A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer (NCT04787289) | British Columbia Cancer Agency | 2021-09-10 |
| 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical (NCT04831307) | British Columbia Cancer Agency | 2021-08-30 |
| 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT) (NCT04610372) | British Columbia Cancer Agency | 2021-07-12 |
| PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc (NCT04814095) | British Columbia Cancer Agency | 2021-06-30 |
| PRecision Oncology Evidence Development in Cancer Treatment - Liquid (NCT05057234) | British Columbia Cancer Agency | 2021-06-18 |
| [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer (NCT04484701) | British Columbia Cancer Agency | 2021-02-01 |
| PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (NCT04015622) | British Columbia Cancer Agency | 2020-10-07 |
| Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer (NCT04705649) | British Columbia Cancer Agency | 2020-07-14 |
| Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (NCT04273061) | British Columbia Cancer Agency | 2020-06-17 |
| Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy (NCT04257396) | British Columbia Cancer Agency | 2020-06-11 |
| 18F-AmBF3-TATE PET/CT for Imaging NET Patients (NCT04207762) | British Columbia Cancer Agency | 2020-06-09 |
| Detection of Covid-19 by Volatile Organic Compounds in Exhaled Breath (NCT04714333) | British Columbia Cancer Agency | 2020-05-06 |
| SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases (NCT03694015) | British Columbia Cancer Agency | 2019-12-02 |
| MSG Use With 18F-DCFPyL PET/CT Imaging (NCT03693742) | British Columbia Cancer Agency | 2019-11-04 |
| Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (NCT03862911) | British Columbia Cancer Agency | 2019-11-01 |
| Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging (NCT04017104) | British Columbia Cancer Agency | 2019-11-01 |
| Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (NCT03917082) | British Columbia Cancer Agency | 2019-09-23 |
| Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease (NCT03836196) | British Columbia Cancer Agency | 2019-09-13 |
| Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer (NCT02574442) | British Columbia Cancer Agency | 2019-09-01 |
| OCT-AF Imaging of Pre-cancers of Vulva and Cervix (NCT03285841) | British Columbia Cancer Agency | 2019-07-25 |
| Efficacy and Safety of Omega 3 Fatty Acid Supplements on Heavy Smokers (NCT03936621) | British Columbia Cancer Agency | 2019-06-01 |
| Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC (NCT03769103) | British Columbia Cancer Agency | 2019-03-19 |
| A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (NCT03450018) | British Columbia Cancer Agency | 2019-01-10 |
| Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers (NCT03790813) | British Columbia Cancer Agency | 2019-01-07 |
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (NCT02978547) | British Columbia Cancer Agency | 2019-01-01 |
| CARA Treatment Pilot Study for Breast Positioning (NCT04543851) | British Columbia Cancer Agency | 2018-10-08 |
| DOTATOC PET/CT for Imaging NET Patients (NCT03583528) | British Columbia Cancer Agency | 2018-07-11 |
| PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. (NCT03283943) | British Columbia Cancer Agency | 2018-04-01 |
| Partial Prostate Salvage High Dose Rate Brachytherapy (NCT03246802) | British Columbia Cancer Agency | 2018-01-01 |
| US-CT Fusion for Post Implant Dosimetry (NCT03692104) | British Columbia Cancer Agency | 2017-11-03 |